May 01, 2019 09:09 JST

Source: Eisai

Eisai Buys Out Purdue Rights to End Collaboration


TOKYO, May 01, 2019 - (JCN Newswire) - Eisai Co., Ltd. announces that its U.S. subsidiary Eisai Inc. has bought out Purdue Pharma L.P.'s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer Disease. Eisai group will solely conduct the development and the commercialization of lemborexant globally.

Discovered by Eisai, lemborexant is an investigational dual orexin receptor antagonist. The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for lemborexant for use in the treatment of insomnia disorders for review in March 2019 and set a Prescription Drug User Fee Act (PDUFA) date for December 27, 2019. For Japan, a marketing authorization application for lemborexant for use in the treatment of insomnia disorder has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in March 2019 and is currently under review. Furthermore, a Phase II clinical study of lemborexant for ISWRD in patients with Alzheimer's Disease is ongoing.

Through lemborexant, Eisai is striving to address unmet medical needs and contribute to further increasing the benefits for patients with sleep disorders and their families.

About Lemborexant

Lemborexant is a novel investigational small molecule compound, discovered and developed by Eisai in-house scientists, that inhibits orexin signaling by binding competitively to both orexin receptor subtypes (orexin receptor 1 and 2). In individuals with normal daily sleep-wake rhythms, orexin signaling is believed to promote periods of wakefulness. In individuals with sleep-wake disorders, it is possible that orexin signaling that regulates wakefulness is not functioning normally, suggesting that inhibiting inappropriate orexin signaling may enable initiation and maintenance of sleep. Additionally, a Phase 2 clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder (ISWRD) and mild to moderate Alzheimer's dementia is underway.


About Eisai
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com


Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech, HealthCare

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID
July 01 2020 13:02 JST
 
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea
June 25 2020 10:47 JST
 
Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa
June 10 2020 12:49 JST
 
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
June 04 2020 10:43 JST
 
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
June 02 2020 10:05 JST
 
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29 2020 14:54 JST
 
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29 2020 10:31 JST
 
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18 2020 12:33 JST
 
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14 2020 08:22 JST
 
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
April 27 2020 16:26 JST
 
More Press release >>

Latest Press Release


More Latest Release >>